Should pharma pay the NIH royalties?

Looking past 2010, when more than $10 billion in fresh federal research funds runs out, the new head of the NIH is hatching a plan to gain a predictable flow of money to back an enlarged commitment to the country's researchers. And one way that the NIH could gain extra financial support, Dr. Francis Collins suggests, is by claiming a royalty from drugs that are developed following federally-supported research efforts. Report

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.